Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12911312 | 0.80 | CA2 (0.42) | CA2CXCR2L3MBTL1 | |
| SCHEMBL15695537 | 0.75 | ALDH1A1 (0.39) | CXCR2 | |
| SCHEMBL8897967 | 0.75 | CXCR2 (0.32) | CXCR2 | |
| SCHEMBL3195088 | 0.72 | HRH3 (0.47) | L3MBTL1 | |
| SCHEMBL4063051 | 0.71 | HRH3 (0.57) | L3MBTL1 | |
| SCHEMBL2223779 | 0.71 | IDH1 (0.35) | CA1CA2GPR84L3MBTL1 | |
| SCHEMBL29724961 | 0.70 | — | — | |
| SCHEMBL4062448 | 0.70 | PYCR1 (0.47) | — | |
| SCHEMBL3183618 | 0.70 | HRH3 (0.60) | L3MBTL1 | |
| SCHEMBL13009655 | 0.69 | CYP4F2 (0.47) | CXCR2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411379-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2014-12-17 | — | — | EP | disclosed |
| US-8703934-B2 | Substituted 4-amino-3,5-dicyano-2-thiopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| US-8673924-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2194058-B1 | Pyrazolopyrimidines suitable for the treatment of cancer diseases | MERCK SHARP & DOHME (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8586576-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-19 | — | — | US | disclosed |
| US-8580782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8318793-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBOTT GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318793-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBOTT GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| CN-102388034-A | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBOTT GMBH & CO KG | 2012-03-21 | — | — | CN | disclosed |
| EP-2411379-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Abbott GmbH & Co. KG (DE) | 2012-02-01 | — | — | EP | disclosed |
| WO-2005077954-A2 | PYRAZOLOPYRIMIDINE-DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050153987-A1 | Compounds | ASTRAZENECA AB (SE) | 2005-07-14 | — | — | US | disclosed |
| EP-1537116-A1 | PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005027823-A2 | 3-HETEROCYCLYL-INDOLE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3 (GSK-3) | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | WO | disclosed |
| EP-1492785-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040209878-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004022561-A1 | PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2003082853-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-10-09 | — | — | WO | disclosed |
| US-5302605-A | 3-Nitromethylidene- or nitroiminoimidazolidin-1-yl-alkylidene derivatives; insecticides; aphidicides; miticides; environmentally safe | CIBA-GEIGY CORPORATION (US) | 1994-04-12 | — | — | US | disclosed |
| CN-1059907-A | PICOLINE OXIDES | CIBA GEIGY AG (CH) | 1992-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209878-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDK5 | CA1 4268/4885CA2 3390/4885CXCR2 2062/4885 |
| US-20050153987-A1 | Compounds | SDHA, CYP11B2, CYP11B1 | CA1 2464/4885CA2 2609/4885CXCR2 1093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.